Active Ingredient(s):Belantamab Mafodotin-blmf FDA Approved: * August 5, 2020 Pharm Company: *GLAXOSMITHKLINE Category:Cancer
Belantamab mafodotin, sold under the brand name Blenrep, is a medication for the treatment of relapsed and refractory multiple myeloma.
The most common adverse reactions include keratopathy (corneal epithelium change on eye exam), decreased visual acuity, nausea, blurred vision, pyrexia, infusion-related reactions, and fatigue.
Belantamab mafodotin is a humanized IgG1κ monocl...
* May have multiple approval dates, manufacturers, or labelers.
Blenrep 50 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution